
Please try another search
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Michael Brennan | - | 2023 | Member of Scientific Advisory Board |
Michael B. Chancellor | 66 | 2005 | Co-Founder, Chief Medical Officer & Director |
Jonathan Kaufman | 58 | 2005 | Co-Founder, Chairman, CEO, President, Secretary & Treasurer |
Naoki Yoshimura | 67 | 2021 | Independent Director & Member of Advisory Board |
Daniel Cohen | 60 | 2023 | Independent Director |
Byong Kim | 54 | 2022 | Independent Director |
Kamal Al-Eryani | - | 2023 | Member of Scientific Advisory Board |
Lori A. Birder | 64 | 2023 | Independent Director |
Jason M. Hafron | - | 2024 | Member of Scientific Advisory Board |
Alessandro Villa | - | 2023 | Chair of the Scientific Advisory Board |
Vidya Sankar | - | 2023 | Member of Scientific Advisory Board |
Ryan Pruchnic | 50 | 2021 | Independent Director |
Herve Y. Sroussi | - | 2023 | Member of Scientific Advisory Board |
Pradeep Tyagi | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review